Disruption of TGF-β growth inhibition hy oncogenic ras is linked to p27Kip1 mislocalization

被引:54
作者
Liu, XD
Sun, Y
Ehrlich, M
Lu, T
Kloog, Y
Weinberg, RA
Lodish, HF
Henis, YI [1 ]
机构
[1] Nine Cambridge Ctr, Whitehead Inst Biomed Res, Cambridge, MA 02142 USA
[2] Tel Aviv Univ, George S Wise Fac Life Sci, Dept Neurobiochem, IL-69978 Tel Aviv, Israel
[3] MIT, Dept Biol, Cambridge, MA 02139 USA
基金
美国国家卫生研究院; 以色列科学基金会;
关键词
mislocalization of p27(Kip1); oncogenic Ras; p27(Kip1) partner switching; TGF-beta growth inhibition;
D O I
10.1038/sj.onc.1203991
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Expression of oncogenic Ras in epithelial tumor cells is linked to the loss of transforming growth factor-beta (TGF-beta) anti-proliferative activity, and was proposed to involve inhibition of Smad2/3 nuclear translocation, Here we studied several epithelial cell lines expressing oncogenic N-Ras(K61) and show that TGF-beta -induced nuclear translocation of and transcriptional activation by Smad2/3,were unaffected. In contrast, oncogenic Ras mediated nuclear-to-cytoplasmic mislocalization of p27(Kip1) (p27) and of the cyclin-dependent kinase (CDK) CDK6, but not CDK2, Concomitantly, oncogenic Ras abrogated the ability of p27 and from to CDK6, to enhance its inhibit CDK2 activity. TGF-beta to binding to Inactivation of Ras by a specific antagonist restored the growth inhibitory response to TGF-beta with concurrent normalization of p27 and CDK6 localization. Therefore, the disruption of TGF-beta -mediated growth inhibition by oncogenic Ras appears to be due to lack of inhibition of CDK2, caused by the sequestration of p27 and CDK2 in different subcellular compartments and by the loss of TGF-beta -induced partner switching of p27 from CDK6 to CDK2.
引用
收藏
页码:5926 / 5935
页数:10
相关论文
共 58 条
[1]  
ALEXANDROW MG, 1995, CANCER RES, V55, P1452
[2]   Overexpressed cyclin D3 contributes to retaining the growth inhibitor p27 in the cytoplasm of thyroid tumor cells [J].
Baldassarre, G ;
Belletti, B ;
Bruni, P ;
Boccia, A ;
Trapasso, F ;
Pentimalli, F ;
Barone, MV ;
Chiappetta, G ;
Vento, MT ;
Spiezia, S ;
Fusco, A ;
Viglietto, G .
JOURNAL OF CLINICAL INVESTIGATION, 1999, 104 (07) :865-874
[3]  
BOS JL, 1989, CANCER RES, V49, P4682
[4]  
Catzavelos C, 1999, CANCER RES, V59, P684
[5]   Activation of the erythropoietin receptor by the gp55-P viral envelope protein is determined by a single amino acid in its transmembrane domain [J].
Constantinescu, SN ;
Liu, XD ;
Beyer, W ;
Fallon, A ;
Shekar, S ;
Henis, YI ;
Smith, SO ;
Lodish, HF .
EMBO JOURNAL, 1999, 18 (12) :3334-3347
[6]   Loss of functional cell surface transforming growth factor beta (TGF-beta) type 1 receptor correlates with insensitivity to TGF-beta in chronic lymphocytic leukemia [J].
DeCoteau, JF ;
Knaus, PI ;
Yankelev, H ;
Reis, MD ;
Lowsky, R ;
Lodish, HF ;
Kadin, ME .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (11) :5877-5881
[7]   Transforming growth factor β1 selectively inhibits the cyclic AMP-dependent proliferation of primary thyroid epithelial cells by preventing the association of cyclin D3-cdk4 with nuclear p27kip1 [J].
Depoortere, F ;
Pirson, I ;
Bartek, J ;
Dumont, JE ;
Roger, PP .
MOLECULAR BIOLOGY OF THE CELL, 2000, 11 (03) :1061-1076
[8]   TGF-BETA INHIBITION OF CDK4 SYNTHESIS IS LINKED TO CELL-CYCLE ARREST [J].
EWEN, ME ;
SLUSS, HK ;
WHITEHOUSE, LL ;
LIVINGSTON, DM .
CELL, 1993, 74 (06) :1009-1020
[9]  
FILMUS J, 1992, ONCOGENE, V7, P521
[10]  
FYNAN TM, 1993, CRIT REV ONCOGENESIS, V4, P493